Chi-Ping Day, Ph.D.
Chi-Ping  Day, Ph.D.
Staff Scientist

Dr. Day's research focuses on the development of transgenic and preclinical models of recurrent and metastatic diseases, and identification of therapeutic targets of metastatic melanoma.

Areas of Expertise
metastatic melanoma

Contact Info

Chi-Ping Day, Ph.D.
Center for Cancer Research
National Cancer Institute
Bldg. 37, Room 5002
Bethesda, MD 20892-4264
301-451-8524
daychi@mail.nih.gov

Dr. Day's research focuses on the development of transgenic and preclinical models of recurrent and metastatic diseases, and identification of therapeutic targets of metastatic melanoma. Inventions 1. Lentiviral vectors for long term in vivo expression of dual fluorescence/luminescence reporters. (2011) Inventors: Dominic Esposito, Chi-Ping Day, and Glenn Merlino. NIH Employee Invention Report Reference No. E‐132‐2011. 2. A bioimaging marker‐tolerant mouse allowing consistent tumor labeling and monitoring in an immunocompetent mouse model. (2010) Inventors: Chi-Ping Day and Glenn Merlino. NIH Employee Invention Report Reference No. E‐173‐2010.

Selected Publications
  1. Day CP, Carter J, Bonomi C, Hollingshead M, Merlino G.
    Int. J. Cancer. 130: 190-9, 2012. [ Journal Article ]
  2. Day CP, Carter J, Bonomi C, Esposito D, Crise B, Ortiz-Conde B, Hollingshead M, Merlino G.
    Pigment Cell Melanoma Res. 22: 283-95, 2009. [ Journal Article ]
  3. Zaidi MR, Day CP, Merlino G.
    J. Invest. Dermatol.. 128: 2381-91, 2008. [ Journal Article ]

Dr. Chi-Ping Day received his BS diploma in chemistry from National Cheng-Kung University, Tainan, Taiwan in 1992 and MS diploma in biochemistry from National Yang-Ming University, Taipei, Taiwan in 1996. He then joined the Graduate School of Biomedical Sciences at the University of Texas Health Science Center at Houston and M. D. Anderson Cancer Center, where he received his Ph.D. in 2005 for his work on the development of breast cancer-specific gene therapy system. In October 2005, he joined the laboratory of Dr. Merlino as a visiting fellow to receive his post-doctoral training, then became Staff Scientist in 2012.

Research

Dr. Day's research focuses on the development of transgenic and preclinical models of recurrent and metastatic diseases, and identification of therapeutic targets of metastatic melanoma. Inventions 1. Lentiviral vectors for long term in vivo expression of dual fluorescence/luminescence reporters. (2011) Inventors: Dominic Esposito, Chi-Ping Day, and Glenn Merlino. NIH Employee Invention Report Reference No. E‐132‐2011. 2. A bioimaging marker‐tolerant mouse allowing consistent tumor labeling and monitoring in an immunocompetent mouse model. (2010) Inventors: Chi-Ping Day and Glenn Merlino. NIH Employee Invention Report Reference No. E‐173‐2010.

Publications

Selected Publications
  1. Day CP, Carter J, Bonomi C, Hollingshead M, Merlino G.
    Int. J. Cancer. 130: 190-9, 2012. [ Journal Article ]
  2. Day CP, Carter J, Bonomi C, Esposito D, Crise B, Ortiz-Conde B, Hollingshead M, Merlino G.
    Pigment Cell Melanoma Res. 22: 283-95, 2009. [ Journal Article ]
  3. Zaidi MR, Day CP, Merlino G.
    J. Invest. Dermatol.. 128: 2381-91, 2008. [ Journal Article ]

Biography

Dr. Chi-Ping Day received his BS diploma in chemistry from National Cheng-Kung University, Tainan, Taiwan in 1992 and MS diploma in biochemistry from National Yang-Ming University, Taipei, Taiwan in 1996. He then joined the Graduate School of Biomedical Sciences at the University of Texas Health Science Center at Houston and M. D. Anderson Cancer Center, where he received his Ph.D. in 2005 for his work on the development of breast cancer-specific gene therapy system. In October 2005, he joined the laboratory of Dr. Merlino as a visiting fellow to receive his post-doctoral training, then became Staff Scientist in 2012.